New Wave Wealth Advisors LLC Makes New $697,000 Investment in Bristol Myers Squibb Company $BMY

by · The Markets Daily

New Wave Wealth Advisors LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,183 shares of the biopharmaceutical company’s stock, valued at approximately $697,000.

A number of other institutional investors have also modified their holdings of BMY. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb during the second quarter valued at approximately $27,000. Bayban bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $32,000. Groupe la Francaise grew its position in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 501 shares in the last quarter. Finally, Arlington Trust Co LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of several research reports. Morgan Stanley reissued an “underweight” rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research report on Wednesday, October 7th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating for the company. Piper Sandler reiterated an “overweight” rating and set a $82.00 target price (up from $75.00) on shares of Bristol Myers Squibb in a research note on Wednesday, September 16th. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.88.

Check Out Our Latest Stock Report on BMY

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.68 during trading on Monday, hitting $59.07. 5,438,418 shares of the company traded hands, compared to its average volume of 12,073,516. The stock has a market capitalization of $120.66 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 0.30 and a beta of 0.19. The business’s fifty day moving average is $63.55 and its 200-day moving average is $60.30. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.56 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).